Estats Units - anglès - NLM (National Library of Medicine)

a-s medication solutions - rabies virus strain flury lep antigen (propiolactone inactivated) (unii: fk894q51ye) (rabies virus strain flury lep antigen (propiolactone inactivated) - unii:fk894q51ye) - rabies virus strain flury lep antigen (propiolactone inactivated) 2.5 [iu] in 1 ml - rabavert is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups. usually, an immunization series is initiated and completed with one vaccine product. no clinical studies have been conducted that document a change in efficacy or the frequency of adverse reactions when the series is completed with a second vaccine product. however, for booster immunization, rabavert was shown to elicit protective antibody level responses in persons tested who received a primary series with hdcv (4,11). (see also dosage and administration section below) preexposure vaccination consists of three doses of rabavert 1.0 ml, intramuscularly (deltoid region), one each on days 0, 7, and 21 or 28 (1) (see also table 1 for criteria for preexposure vaccination). preexposure vaccination does not eliminate the need for additional therapy after a known rabies exposure (see also dosage and administration section, subsection c). preexposure vaccina

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rabies virus -

Unió Europea - anglès - EMA (European Medicines Agency)

zoetis belgium sa - canine distemper virus, strain cdv bio 11/a, canine adenovirus type 2, strain cav-2 bio 13, canine parvovirus type 2b, strain cpv-2b bio 12/b, canine parainfluenza type 2 virus, strain cpiv-2 bio 15 (all live attenuated), leptospira interrogans serogroup australis serovar bratislava, strain mslb 1088, l. interrogans serogroup icterohaemorrhagiae serovar icterohaemorrhagiae, strain mslb 1089, l. interrogans serogroup canicola serovar canicola, strain mslb 1090, l. kirschneri serogroup grippotyphosa serovar grippotyphosa, strain mslb 1091... - live canine distemper virus + live canine adenovirus + live parainfl.virus + live canine parvovirus + inactivated rabies + inactivated leptospira, immunologicals for canidae - dogs - active immunisation of dogs from 8–9 weeks of age:to prevent mortality and clinical signs caused by canine distemper virus,to prevent mortality and clinical signs caused by canine adenovirus type 1,to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2,to prevent clinical signs, leucopoenia and viral excretion caused by canine parvovirus,to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus,to prevent clinical signs, infection and urinary excretion caused by l. interrogans serogroup australis serovar bratislava,to prevent clinical signs and urinary excretion and reduce infection caused by l. interrogans serogroup canicola serovar canicola and l. interrogans serogroup icterohaemorrhagie serovar icterohaemorrhagiae,to prevent clinical signs and reduce infection and urinary excretion caused by l. interrogans serogroup grippotyphosa serovar grippotyphosa and to prevent mortality, clinical signs and infection caused by rabies virus.

Unió Europea - anglès - EMA (European Medicines Agency)

zoetis belgium s.a. - canine parainfluenza virus, leptospira and rabies virus. - immunologicals for canidae, live and inactivated viral and bacterial vaccines - dogs - active immunization of dogs from six weeks of age to prevent clinical signs and reduce viral excretion cause by canine parainfluenza virus, to prevent clinical signs, infection and urinary excretion cause by leptospira serovars bratislava, canicola, grippotyphosa and icterohaemorrhagiae and to prevent mortality, clinical signs and infection cause by rabies virus.

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - rabies virus inactivated - powder and solvent for suspension for injection

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - rabies virus inactivated - powder and solvent for suspension for injection

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - rabies virus inactivated - powder and solvent for solution for injection

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - rabies virus inactivated - powder and solvent for suspension for injection

Espanya - anglès - HMA (Heads of Medicines Agencies)

pfizer limited - canine adenovirus 4.9 gkid50, canine distemper virus 4.7 gkid50, canine parainfluenza virus 4.6 gkid50, canine parvovirus 6.1 gkid50, leptospira interrogans serogroup canicola 32 malr, leptospira interrogans serogroup icterohaemorragiae 32 malr, rabies virus, inactivated 2 iu - suspension for injection - dogs non food - live canine distemper virus + live canine adenovirus + live parainfl.virus + live canine parvovirus + inactivated rabies + inact

Àustria - anglès - HMA (Heads of Medicines Agencies)

pfizer limited - canine adenovirus 4.9 gkid50, canine distemper virus 4.7 gkid50, canine parainfluenza virus 4.6 gkid50, canine parvovirus 6.1 gkid50, leptospira interrogans serogroup canicola 32 malr, leptospira interrogans serogroup icterohaemorragiae 32 malr, rabies virus, inactivated 2 iu - suspension for injection - dogs non food - live canine distemper virus + live canine adenovirus + live parainfl.virus + live canine parvovirus + inactivated rabies + inact